Vigilant Capital Management LLC Has $49,000 Position in Gilead Sciences, Inc. (GILD)

Vigilant Capital Management LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 81.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 752 shares of the biopharmaceutical company’s stock after selling 3,404 shares during the quarter. Vigilant Capital Management LLC’s holdings in Gilead Sciences were worth $49,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of GILD. Athena Capital Advisors LLC acquired a new position in Gilead Sciences during the 4th quarter valued at $27,000. Capital Financial Planning LLC acquired a new position in Gilead Sciences during the 4th quarter valued at $27,000. Advisors Preferred LLC acquired a new position in Gilead Sciences during the 4th quarter valued at $31,000. Legacy Financial Advisors Inc. raised its stake in Gilead Sciences by 361.3% during the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 383 shares during the last quarter. Finally, Claybrook Capital LLC acquired a new position in Gilead Sciences during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 80.27% of the company’s stock.

In other Gilead Sciences news, Director John Francis Cogan sold 2,868 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total transaction of $186,104.52. Following the sale, the director now owns 57,728 shares of the company’s stock, valued at approximately $3,745,969.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard James Whitley sold 9,534 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the sale, the director now directly owns 34,669 shares in the company, valued at approximately $2,270,126.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,670 shares of company stock worth $3,142,526. 0.20% of the stock is owned by insiders.

Shares of GILD stock traded up $1.83 during mid-day trading on Friday, reaching $67.13. The company’s stock had a trading volume of 8,757,689 shares, compared to its average volume of 7,412,155. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $79.61. The stock has a market cap of $85.58 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 0.85 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the prior year, the firm earned $1.48 EPS. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 6.3 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.75%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s payout ratio is 40.98%.

Several research firms recently commented on GILD. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Mizuho reiterated a “buy” rating and set a $88.00 target price on shares of Gilead Sciences in a research note on Tuesday, February 26th. Citigroup cut shares of Gilead Sciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $100.00 to $75.00 in a research note on Tuesday, February 12th. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Raymond James set a $86.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, April 23rd. Nine research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $81.47.

ILLEGAL ACTIVITY WARNING: “Vigilant Capital Management LLC Has $49,000 Position in Gilead Sciences, Inc. (GILD)” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/vigilant-capital-management-llc-has-49000-holdings-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

See Also: Do Tariffs Work?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.